<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sensus Healthcare Inc — News on 6ix</title>
<link>https://6ix.com/company/sensus-healthcare-inc</link>
<description>Latest news and press releases for Sensus Healthcare Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 21:56:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sensus-healthcare-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c3fe78dffbe2df119ffa.webp</url>
<title>Sensus Healthcare Inc</title>
<link>https://6ix.com/company/sensus-healthcare-inc</link>
</image>
<item>
<title>Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-to-report-first-quarter-2026-financial-results-and-hold-business-update-conference-call-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-to-report-first-quarter-2026-financial-results-and-hold-business-update-conference-call-on-may-7-2026</guid>
<pubDate>Thu, 23 Apr 2026 21:56:00 GMT</pubDate>
<description>BOCA RATON, Fla., April 23, 2026--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the first quarter of 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.</description>
</item>
<item>
<title>Sensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-files-lawsuit-against-skincure-oncology-for-breach-of-contract</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-files-lawsuit-against-skincure-oncology-for-breach-of-contract</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>BOCA RATON, Fla.--(BUSINESS WIRE)-- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive,</description>
</item>
<item>
<title>Sensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-introduces-sensus-link-brings-advanced-operating-capabilities-to-the-srt-100tm-installed-base</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-introduces-sensus-link-brings-advanced-operating-capabilities-to-the-srt-100tm-installed-base</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Proprietary cloud-based software and add-on solution designed to provide current and future SRT-100 users with enhanced workflow, operating intelligence and</description>
</item>
<item>
<title>Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-launches-sensus-healthcare-financial-133000186</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-launches-sensus-healthcare-financial-133000186</guid>
<pubDate>Wed, 18 Feb 2026 13:30:00 GMT</pubDate>
<description>BOCA RATON, Fla., February 18, 2026--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the launch of Sensus Healthcare Financial Services, a new program intended to make it easier for dermatology practices to acquire Sensus’ superficial radiotherapy (SRT) systems through a streamlined process and flexible financing structur</description>
</item>
<item>
<title>Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-reports-fourth-quarter-210500649</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-reports-fourth-quarter-210500649</guid>
<pubDate>Thu, 12 Feb 2026 21:05:00 GMT</pubDate>
<description>BOCA RATON, Fla., February 12, 2026--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and twelve months ended December 31, 2025.</description>
</item>
<item>
<title>Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-report-fourth-quarter-130000137</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-report-fourth-quarter-130000137</guid>
<pubDate>Thu, 05 Feb 2026 13:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., February 05, 2026--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and an</description>
</item>
<item>
<title>Sensus Healthcare to Hold Investor Meetings During JPM Week 2026 in San Francisco</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-hold-investor-meetings-213000540</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-hold-investor-meetings-213000540</guid>
<pubDate>Wed, 07 Jan 2026 21:30:00 GMT</pubDate>
<description>BOCA RATON, Fla., January 07, 2026--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that management will be meeting with members of the healthcare investment community January 12–14, 2026, in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference.</description>
</item>
<item>
<title>Sensus Healthcare Appoints Larry Biscotti to its Board of Directors</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-appoints-larry-biscotti-133000187</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-appoints-larry-biscotti-133000187</guid>
<pubDate>Wed, 07 Jan 2026 13:30:00 GMT</pubDate>
<description>BOCA RATON, Fla., January 07, 2026--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors.</description>
</item>
<item>
<title>Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-expands-role-president-130000797</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-expands-role-president-130000797</guid>
<pubDate>Fri, 14 Nov 2025 13:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., November 14, 2025--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that President Michael Sardano has been appointed to the additional role of Chief Commercial Officer. In this newly created position, Mr. Sardano will direct the company’s global sales, marketing and commercial strategy across its p</description>
</item>
<item>
<title>Sensus Healthcare Appoints Eric Sachetta to its Board of Directors</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-appoints-eric-sachetta-130000219</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-appoints-eric-sachetta-130000219</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., November 12, 2025--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Eric Sachetta to the Company’s Board of Directors. Mr. Sachetta is filling the vacancy that resulted from the passing of long-serving Director Bill McCall.</description>
</item>
<item>
<title>Sensus Healthcare Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-reports-third-quarter-210500061</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-reports-third-quarter-210500061</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>BOCA RATON, Fla., November 06, 2025--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and nine months ended September 30, 2025.</description>
</item>
<item>
<title>Sensus Healthcare Named to TIME’s America’s Growth Leaders of 2026</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-named-time-america-130000737</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-named-time-america-130000737</guid>
<pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., November 06, 2025--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that it has been named to TIME’s list of America’s Growth Leaders of 2026, developed in partnership with Statista Inc.</description>
</item>
<item>
<title>CMS Establishes Coding Validating Sensus SRT for Treating Non-Melanoma Skin Cancer</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/cms-establishes-coding-validating-sensus-130000042</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/cms-establishes-coding-validating-sensus-130000042</guid>
<pubDate>Tue, 04 Nov 2025 13:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., November 04, 2025--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that the Centers for Medicare & Medicaid Services (CMS) has published a distinct set of treatment codes specific to the use of superficial radiotherapy (SRT and IG-SRT) for non-melanoma skin cancer (NMSC).</description>
</item>
<item>
<title>Sensus Healthcare Announces the Passing of Director Bill McCall</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-announces-passing-director-120000280</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-announces-passing-director-120000280</guid>
<pubDate>Fri, 31 Oct 2025 12:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., October 31, 2025--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the passing of longtime friend of the Company and current Director William "Bill" McCall.</description>
</item>
<item>
<title>Sensus Healthcare to Report Third Quarter 2025 Financial Results and Hold Business Update Conference Call on November 6</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-report-third-quarter-120000849</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-report-third-quarter-120000849</guid>
<pubDate>Thu, 23 Oct 2025 12:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., October 23, 2025--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the third quarter of 2025 on Thursday, November 6, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer q</description>
</item>
<item>
<title>Study Published in Dermatologic Therapy Shows Efficacy of Sensus Healthcare’s SRT Combined with Punch Excision to Treat Keloids</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/study-published-dermatologic-therapy-shows-120000189</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/study-published-dermatologic-therapy-shows-120000189</guid>
<pubDate>Tue, 23 Sep 2025 12:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., September 23, 2025--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that a study published in Dermatologic Therapy demonstrates the safety and efficacy of the Company’s superficial radiotherapy (SRT) technology combined with punch excision to treat keloids.</description>
</item>
<item>
<title>Sensus Healthcare Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-reports-second-quarter-200500453</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-reports-second-quarter-200500453</guid>
<pubDate>Thu, 07 Aug 2025 20:05:00 GMT</pubDate>
<description>BOCA RATON, Fla., August 07, 2025--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and six months ended June 30, 2025.</description>
</item>
<item>
<title>Sensus Healthcare to Report Second Quarter 2025 Financial Results and Hold Business Update Conference Call on August 7</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-report-second-quarter-201500942</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-report-second-quarter-201500942</guid>
<pubDate>Thu, 24 Jul 2025 20:15:00 GMT</pubDate>
<description>BOCA RATON, Fla., July 24, 2025--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report financial results for the second quarter of 2025 on Thursday, August 7, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer quest</description>
</item>
<item>
<title>Receipt of MDSAP Certification for Sensus Healthcare’s Full SRT Product Portfolio to Streamline and Accelerate International Sales Efforts</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/receipt-mdsap-certification-sensus-healthcare-120000859</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/receipt-mdsap-certification-sensus-healthcare-120000859</guid>
<pubDate>Thu, 24 Jul 2025 12:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., July 24, 2025--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that its entire portfolio of superficial radiation therapy (SRT) systems – including the SRT-100®, SRT-100+™ and SRT-100 Vision™ – has received certification under the Medical Device Single Audit Program (MDSAP). This certification is expecte</description>
</item>
<item>
<title>Sensus Healthcare Engages Radiology Oncology Systems (ROS) as Primary Distribution Partner for its SRT Systems to Radiation Oncologists</title>
<link>https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-engages-radiology-oncology-120000837</link>
<guid isPermaLink="true">https://6ix.com/company/sensus-healthcare-inc/news/sensus-healthcare-engages-radiology-oncology-120000837</guid>
<pubDate>Thu, 26 Jun 2025 12:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., June 26, 2025--Sensus Healthcare, Inc. (Nasdaq: SRTS) (Sensus or the Company), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it has entered into a strategic agreement with Radiology Oncology Systems (ROS) to serve as the Company’s primary distribution partner for the U.S. radiation oncology market. Under the terms of the agreement, ROS will</description>
</item>
</channel>
</rss>